Two responders had colorectal cancer; one was microsatellite stable, PD-1 naive, and was enrolled in the 30mg livmoniplimab combination cohort, and another, who was microsatellite instability low (retrospective tumor tissue testing by whole exome sequencing at AbbVie), was enrolled in the 100mg livmoniplimab combination cohort and received, and responded to, prior PD-1 and cytotoxic T-lymphocyte antigen 4 combination checkpoint inhibitor therapy. This evidence concerns the gene PDCD1 and neoplasm.